Heart patients get a helping hand: new care model boosts medication adherence

NCT ID NCT07346664

Completed Disease control Sponsor: Qing Wang Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested a transitional care model for 108 patients with coronary heart disease who had a stent procedure. The program used structured follow-up and WeChat-based education to help patients take their medications correctly and improve self-care. Researchers measured medication adherence, self-efficacy, and cholesterol levels to see if the extra support made a difference.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: transitional care model (structured follow-up and education via WeChat)
What this could lead to: If it works, this could point toward a simple, low-cost way to help heart patients stay on track with their medications and lifestyle changes after a procedure.
What could go wrong: This is a small, single-center study with no blinding, so results may not apply to all heart patients. The intervention is behavioral, not a drug, so effects may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY HEART DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder Coronary Disease Medication Adherence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY HEART DISEASE LIPID PROFILE MEDICATION ADHERENCE SELF EFFICACY TRANSITIONAL CARE MODEL

Contacts and locations

Locations

Northern Jiangsu People's Hospital Affiliated to Yangzhou University

Yangzhou, Jiangsu, 225001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.